Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:INVA
- CUSIP: 88338T10
- Web: www.inva.com
Capitalization:- Market Cap: $1.51682 billion
- Outstanding Shares: 109,361,000
Average Prices:- 50 Day Moving Avg: $13.18
- 200 Day Moving Avg: $12.81
- 52 Week Range: $8.67 - $14.55
P/E:- Trailing P/E Ratio: 17.37
- Foreward P/E Ratio: 7.80
- P/E Growth: 0.28
Sales & Book Value:- Annual Revenue: $175.98 million
- Price / Sales: 8.58
- Book Value: ($2.71) per share
- Price / Book: -5.10
Profitability:- EBIDTA: $142.91 million
- Net Margins: 52.56%
- Return on Equity: -27.37%
- Return on Assets: 24.45%
Debt:- Debt-to-Equity Ratio: -2.15%
- Current Ratio: 7.31%
- Quick Ratio: 7.31%
Misc:- Average Volume: 952,512 shs.
- Beta: 2.58
- Short Ratio: 16.67
Frequently Asked Questions for Innoviva (NASDAQ:INVA)
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva, Inc. (NASDAQ:INVA) issued its earnings results on Wednesday, July, 26th. The company reported $0.30 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.28 by $0.02. The business earned $58.60 million during the quarter, compared to analyst estimates of $50.53 million. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. Innoviva's revenue was up 80.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 EPS. View Innoviva's Earnings History.
Where is Innoviva's stock going? Where will Innoviva's stock price be in 2017?
3 equities research analysts have issued 1 year price targets for Innoviva's stock. Their predictions range from $13.00 to $16.00. On average, they anticipate Innoviva's stock price to reach $14.67 in the next twelve months. View Analyst Ratings for Innoviva.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Horizon Pharma PLC (HZNP), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), AKCEA THERAPEUT (AKCA), Emergent Biosolutions (EBS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Lannett Co (LCI), SciClone Pharmaceuticals (SCLN), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH) and Corium International (CORI).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- William H. Waltrip, Independent Chairman of the Board
- Eric D'Esparbes, Chief Financial Officer, Senior Vice President
- Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer
- Michael E. Faerm, Senior Vice President and Chief Business Officer
- Michael W. Aguiar, President, Chief Executive Officer, Director
- Barbara G. Duncan, Independent Director
- Catherine J. Friedman, Independent Director
- Patrick G. LePore, Independent Director
- Paul A. Pepe, Independent Director
Who owns Innoviva stock?
Innoviva's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.88%), BlackRock Inc. (11.12%), Vanguard Group Inc. (6.93%), State Street Corp (2.48%), First Eagle Investment Management LLC (2.49%) and Wells Fargo & Company MN (1.86%). Company insiders that own Innoviva stock include Eric Desparbes, James L Tyree, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.
Who sold Innoviva stock? Who is selling Innoviva stock?
Innoviva's stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Empyrean Capital Partners LP, Icon Advisers Inc. Co., Wells Fargo & Company MN, Old Mutual Global Investors UK Ltd., OxFORD Asset Management LLP, State of New Jersey Common Pension Fund D and JPMorgan Chase & Co.. Company insiders that have sold Innoviva stock in the last year include Eric Desparbes, Theodore J Jr Witek and Theodore L Witek Jr. View Insider Buying and Selling for Innoviva.
Who bought Innoviva stock? Who is buying Innoviva stock?
Innoviva's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Dimensional Fund Advisors LP, Gotham Asset Management LLC, PDT Partners LLC, Acadian Asset Management LLC, State Street Corp and Spark Investment Management LLC. View Insider Buying and Selling for Innoviva.
How do I buy Innoviva stock?
Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of Innoviva stock can currently be purchased for approximately $13.81.
MarketBeat Community Rating for Innoviva (NASDAQ INVA)MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Innoviva (NASDAQ:INVA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $14.67 (6.20% upside) |
Analysts' Ratings History for Innoviva (NASDAQ:INVA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/15/2017 | Stifel Nicolaus | Reiterated Rating | Hold -> Neutral | | Low |  |
| 7/28/2017 | Cowen and Company | Set Price Target | Buy | $16.00 | Medium | |
| 7/27/2017 | Robert W. Baird | Reiterated Rating | Neutral | $11.00 -> $13.00 | Medium | |
| 10/5/2015 | Morgan Stanley | Reiterated Rating | Overweight | $7.00 -> $9.00 | N/A | |
(Data available from 9/19/2015 forward)
Earnings History for Innoviva (NASDAQ:INVA)Earnings History by Quarter for Innoviva (NASDAQ INVA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/26/2017 | Q2 2017 | $0.28 | $0.30 | $50.53 million | $58.60 million | View | N/A | |
| 4/27/2017 | Q1 2017 | $0.27 | $0.15 | $47.66 million | $40.50 million | View | N/A | |
| 2/9/2017 | Q4 2016 | $0.19 | $0.22 | $40.72 million | $43.60 million | View | Listen | |
| 10/27/2016 | Q316 | $0.19 | $0.16 | $38.71 million | $33.30 million | View | Listen | |
| 7/28/2016 | Q216 | $0.12 | $0.17 | $31.13 million | $32.47 million | View | Listen | |
| 4/28/2016 | Q116 | $0.09 | $0.04 | $28.61 million | $24.17 million | View | Listen | |
| 2/3/2016 | Q415 | $0.01 | $0.04 | $20.17 million | $22.80 million | View | N/A | |
| 10/28/2015 | Q315 | ($0.03) | ($0.04) | $15.23 million | $13.56 million | View | Listen | |
| 7/29/2015 | Q2 | ($0.06) | ($0.07) | $10.90 million | $10.70 million | View | Listen | |
| 5/6/2015 | Q115 | ($0.08) | ($0.09) | $8.64 million | $6.90 million | View | Listen | |
| 2/18/2015 | Q414 | ($0.14) | ($0.14) | $5.42 million | $7.30 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.15) | ($0.19) | $5.06 million | $1.00 million | View | N/A | |
| 8/18/2014 | | ($0.53) | ($0.18) | | | View | N/A | |
| 8/6/2014 | Q214 | ($0.53) | ($0.18) | $4.39 million | $0.93 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.53) | ($0.62) | $4.52 million | $0.17 million | View | N/A | |
| 2/6/2014 | Q413 | ($0.38) | ($0.46) | $6.03 million | $1.60 million | View | N/A | |
| 10/24/2013 | Q313 | $0.69 | ($0.44) | $3.08 million | $0.44 million | View | N/A | |
| 7/25/2013 | Q2 2013 | ($0.46) | ($0.37) | $1.43 million | $1.33 million | View | N/A | |
| 4/25/2013 | Q1 2013 | ($0.38) | ($0.39) | $2.71 million | $1.34 million | View | N/A | |
| 2/12/2013 | Q4 2012 | ($0.36) | ($0.33) | $3.88 million | $5.80 million | View | N/A | |
| 10/30/2012 | | ($0.39) | ($0.37) | | | View | N/A | |
| 7/31/2012 | | ($0.42) | ($0.42) | | | View | N/A | |
| 4/26/2012 | | $1.02 | $0.93 | | | View | N/A | |
| 2/9/2012 | | ($0.38) | ($0.45) | | | View | N/A | |
| 10/27/2011 | | ($0.33) | ($0.37) | | | View | N/A | |
| 7/28/2011 | | ($0.27) | ($0.31) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Innoviva (NASDAQ:INVA)Current Year EPS Consensus Estimate: $1.16 EPS
Next Year EPS Consensus Estimate: $1.77 EPS
Dividend History by Quarter for Innoviva (NASDAQ INVA)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/30/2015 | quarterly | $0.25 | 7.01% | 9/8/2015 | 9/10/2015 | 9/30/2015 |
| 5/7/2015 | quarterly | $0.25 | 6.43% | 6/10/2015 | 6/12/2015 | 6/30/2015 |
| 2/24/2015 | quarterly | $0.25 | 5.85% | 3/10/2015 | 3/12/2015 | 3/31/2015 |
| 10/31/2014 | quarterly | $0.25 | 6.24% | 11/21/2014 | 11/25/2014 | 12/23/2014 |
| 8/6/2014 | quarterly | $0.25 | | 8/26/2014 | 8/28/2014 | 9/18/2014 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Innoviva (NASDAQ:INVA)Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 69.06%
Insider Trades by Quarter for Innoviva (NASDAQ:INVA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/21/2017 | Eric Desparbes | CFO | Sell | 1,825 | $12.20 | $22,265.00 | |
| 5/22/2017 | Eric Desparbes | CFO | Sell | 1,825 | $11.85 | $21,626.25 | |
| 5/22/2017 | Theodore J Jr. Witek | VP | Sell | 7,815 | $12.01 | $93,858.15 | |
| 2/21/2017 | Eric Desparbes | CFO | Sell | 1,825 | $12.07 | $22,027.75 | |
| 11/22/2016 | Theodore L Witek Jr | VP | Sell | 3,700 | $10.84 | $40,108.00 | |
| 11/21/2016 | Eric Desparbes | CFO | Sell | 1,800 | $10.89 | $19,602.00 | |
| 8/22/2016 | Eric Desparbes | CFO | Sell | 3,700 | $11.77 | $43,549.00 | |
| 5/18/2016 | James L Tyree | Director | Sell | 813 | $10.47 | $8,512.11 | |
| 5/11/2015 | Plc Glaxosmithkline | Major Shareholder | Buy | 85,579 | $1,369,260.00 | $117,179,901,540.00 | |
| 8/13/2014 | Junning Lee | VP | Sell | 53,424 | $22.50 | $1,202,040.00 | |
| 8/12/2014 | Bradford J Shafer | SVP | Sell | 28,156 | $22.13 | $623,092.28 | |
| 8/11/2014 | Bradford J Shafer | SVP | Sell | 27,108 | $22.12 | $599,628.96 | |
| 9/12/2013 | Rick Winningham | CEO | Sell | 22,353 | $40.03 | $894,790.59 | |
| 7/30/2013 | Mathai Mammen | SVP | Sell | 7,000 | $36.51 | $255,570.00 | |
| 6/7/2013 | Bradford J Shafer | SVP | Sell | 31,038 | $35.04 | $1,087,571.52 | |
| 5/29/2013 | David L Brinkley | Insider | Sell | 3,808 | $35.01 | $133,318.08 | |
| 5/13/2013 | David L Brinkley | Insider | Sell | 16,129 | $40.33 | $650,482.57 | |
| 8/7/2012 | Michael W Aguiar | CFO | Sell | 60,000 | $27.04 | $1,622,400.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Innoviva (NASDAQ:INVA)
Latest Headlines for Innoviva (NASDAQ:INVA)
| Source: |
|
| Date | Headline |
|---|
 | Financial Contrast: Opko Health (OPK) versus Innoviva (INVA)
www.americanbankingnews.com - September 19 at 8:52 AM |
 | Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
finance.yahoo.com - September 18 at 7:26 PM |
| Innoviva, Inc. (INVA) Given "Neutral" Rating at Stifel Nicolaus
www.americanbankingnews.com - September 16 at 9:40 PM |
 | Innoviva (INVA) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 8 at 11:39 PM |
| Innoviva to Participate in Morgan Stanley’s Global Healthcare Unplugged Conference on September 12
finance.yahoo.com - September 7 at 8:13 PM |
| $57.42 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter
www.americanbankingnews.com - September 7 at 5:50 AM |
| $0.32 Earnings Per Share Expected for Innoviva, Inc. (INVA) This Quarter
www.americanbankingnews.com - September 5 at 10:26 AM |
| Innoviva, Inc. (INVA) Downgraded by ValuEngine to Hold
www.americanbankingnews.com - September 3 at 9:02 AM |
| Innoviva to Participate in Baird Global Healthcare Conference on September 7
finance.yahoo.com - August 31 at 6:15 AM |
| Stocks Showing Improving Market Leadership: Innoviva Earns 84 RS Rating
finance.yahoo.com - August 30 at 2:25 AM |
| Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : August 28, 2017
finance.yahoo.com - August 28 at 7:32 PM |
| Innoviva, Inc. – Value Analysis (NASDAQ:INVA) : August 21, 2017
finance.yahoo.com - August 23 at 5:24 AM |
| Eric Desparbes Sells 1,825 Shares of Innoviva, Inc. (INVA) Stock
www.americanbankingnews.com - August 22 at 8:22 PM |
| Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes
finance.yahoo.com - August 21 at 8:53 AM |
| Brokerages Anticipate Innoviva, Inc. (INVA) Will Announce Quarterly Sales of $57.42 Million
www.americanbankingnews.com - August 19 at 1:18 AM |
| Zacks: Brokerages Expect Innoviva, Inc. (INVA) Will Announce Earnings of $0.31 Per Share
www.americanbankingnews.com - August 17 at 10:24 PM |
| Innoviva, Inc. (INVA) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - August 16 at 10:56 PM |
| Tracking Seth Klarman's Baupost Group Holdings - Q2 2017 Update
seekingalpha.com - August 12 at 4:48 AM |
| See what the IHS Markit Score report has to say about Innoviva Inc.
finance.yahoo.com - August 9 at 8:12 PM |
| Innoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : August 9, 2017
finance.yahoo.com - August 9 at 8:12 PM |
| Innoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers’ $17.5 million Over-Allotment Option
finance.yahoo.com - August 7 at 7:23 PM |
| Illumina (ILMN) Catches Eye: Stock Soars 14.8%
finance.yahoo.com - August 3 at 8:02 PM |
| Innoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes
finance.yahoo.com - August 1 at 8:31 PM |
| Innoviva, Inc. -- Moody's assigns B3 CFR to Innoviva; stable outlook
finance.yahoo.com - August 1 at 3:31 PM |
| $52.12 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter
www.americanbankingnews.com - August 1 at 8:05 AM |
| ETFs with exposure to Innoviva, Inc. : July 31, 2017
finance.yahoo.com - July 31 at 7:18 PM |
| Innoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes
finance.yahoo.com - July 31 at 7:18 PM |
| Innoviva, Inc. (INVA) Expected to Post Earnings of $0.32 Per Share
www.americanbankingnews.com - July 30 at 4:28 PM |
| Innoviva, Inc. (NASDAQ:INVA) Earns Neutral Rating from Robert W. Baird
www.americanbankingnews.com - July 27 at 11:00 PM |
| Edited Transcript of INVA earnings conference call or presentation 26-Jul-17 9:00pm GMT
finance.yahoo.com - July 27 at 10:58 PM |
| Innoviva, Inc. (INVA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - July 26 at 9:14 PM |
| Innoviva Reports Strong Second Quarter 2017 Financial Results
finance.yahoo.com - July 26 at 8:13 PM |
| Innoviva beats 2Q profit forecasts
finance.yahoo.com - July 26 at 8:13 PM |
 | GSK Submits EU Filing For Extended Use Of Relvar Ellipta
www.rttnews.com - July 21 at 4:13 PM |
| GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination
finance.yahoo.com - July 21 at 4:13 PM |
| Innoviva to Report First Quarter Financial Results on July 26 at 5:00 p.m. EDT
finance.yahoo.com - July 19 at 10:18 PM |
| Innoviva, Inc. (NASDAQ:INVA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 18 at 12:27 AM |
 | Initiating Research Reports on Application Software Equities -- Sphere 3D ...
www.prnewswire.com - July 17 at 8:21 AM |
 | Initiating Research Reports on Application Software Equities -- Sphere 3D, Cadence Design Systems, Innoviva, and Shopify
www.bizjournals.com - July 17 at 8:21 AM |
| ETFs with exposure to Innoviva, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 7:56 PM |
| Zacks: Analysts Expect Innoviva, Inc. (NASDAQ:INVA) Will Post Quarterly Sales of $49.12 Million
www.americanbankingnews.com - July 8 at 9:38 AM |
| Zacks: Analysts Anticipate Innoviva, Inc. (INVA) Will Announce Earnings of $0.28 Per Share
www.americanbankingnews.com - July 6 at 12:19 PM |
| Innoviva, Inc. (INVA) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 4 at 12:36 AM |
| ETFs with exposure to Innoviva, Inc. : June 20, 2017
finance.yahoo.com - June 20 at 6:52 PM |
| Innoviva, Inc. :INVA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 19 at 12:19 PM |
| Innoviva, Inc. (INVA) Expected to Announce Quarterly Sales of $49.12 Million
www.americanbankingnews.com - June 14 at 11:50 AM |
| Zacks: Brokerages Anticipate Innoviva, Inc. (INVA) to Post $0.28 Earnings Per Share
www.americanbankingnews.com - June 12 at 2:32 PM |
| Innoviva Inc (INVA) Sees Significant Decline in Short Interest
www.americanbankingnews.com - June 9 at 3:50 PM |
| ValuEngine Downgrades Innoviva Inc (INVA) to Hold
www.americanbankingnews.com - June 4 at 10:38 AM |
| Can This Biotech Stock With 645% EPS Growth Launch New Breakout?
finance.yahoo.com - June 2 at 7:20 PM |
Innoviva (INVA) Chart for Tuesday, September, 19, 2017
